EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Parkinson's Disease Drug Tolcapone and Analogues are Potent Glycomimetic Lectin Inhibitors of Pseudomonas aeruginosa LecA

Steffen Leusmann iD, Eike Siebs iD, Sakonwan Kuhaudomlarp iD, Annabelle Varrot iD, Anne Imberty iD, Bernd Kuhn iD, Christian Lerner iD, Uwe Grether iD, Alexander Titz iD

Angewandte Chemie International Edition · 2025

DOI: 10.1002/anie.202508864 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2025. Verfasst von Steffen Leusmann und 8 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Biology of Carbohydrates (CBCH), Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, 6…. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Adhesins, Bacterial, Benzophenones, Lectins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PROXIMA1, ANR/DFG French-German project, Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The notorious pathogen Pseudomonas aeruginosa relies on the lectin LecA for host cell adhesion, invasion, and biofilm formation. Motivated by the pressing need for new anti‐infective therapies caused by antimicrobial resistance, inhibitors of LecA are under investigation. Complementary to the use of carbohydrate‐based inhibitors, we have previously identified catechols as weak but specific ligands of LecA, constituting a novel class of non‐carbohydrate glycomimetics. By growing the initial millimolar fragment hits, we identified Tolcapone as a promising compound. To gain insight into the structure‐activity relationship (SAR) of catechols as LecA binders, more than 3,200 compounds of the Roche in‐house library were experimentally screened in a competitive binding assay at three concentrations. Of these, 48 compounds were chosen for further investigation, resulting in compounds equipotent to aryl galactosides, the current epitome of LecA inhibition. X‐ray crystallography and saturation transfer difference (STD) NMR spectroscopy revealed conserved interactions of the catechol moiety in the glycan binding site of LecA and rationalized the observed SAR. Our findings demonstrate that it is possible to develop potent non‐carbohydrate glycomimetic lectin inhibitors. This work paves the way for a new avenue of research towards innovative anti‐infective drugs. In a more general perspective, such small molecules also hold potential to challenge the hegemony of antibodies for lectin inhibition in clinical use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaAdhesins, BacterialBenzophenonesLectinsAnti-Bacterial AgentsStructure-Activity RelationshipCrystallography, X-RayCatecholsMolecular StructureHumans

Stichwörter der Autor:innen

CatecholsDrug repurposingGlycomimeticsInhibitorsLectins

Substanzen

LecA protein, bacteriaAdhesins, BacterialBenzophenonesLectinsCatecholsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Chemical Biology of Carbohydrates (CBCH), Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, 66123, Saarbrücken, Germany.
  • Department of Chemistry, PharmaScienceHub (PSH), Saarland University, 66123, Saarbrücken, Germany.
  • Deutsches Zentrum für Infektionsforschung (DZIF), Standort Hannover-Braunschweig, Germany.
  • Univ. Grenoble Alpes, Centre National de la Recherche Scientifique (CNRS), Centre de Recherches sur les Macromolécules Végétales (CERMAV), Grenoble, 38000, France.
  • Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok, 10400, Thailand.
  • Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, 4070, Switzerland.

ORCID-Profile: Steffen Leusmann, Eike Siebs, Sakonwan Kuhaudomlarp, Annabelle Varrot, Anne Imberty, Bernd Kuhn, Christian Lerner, Uwe Grether, Alexander Titz

Förderung

  • PROXIMA1
  • ANR/DFG French-German project
  • Agence Nationale de la Recherche
  • Deutsche Forschungsgemeinschaft
  • Glyco@Alps
  • Labex Arcane/CBH-EUR-GS
  • EU COST Action

Zitieren

APA

Leusmann, S., Siebs, E., Kuhaudomlarp, S., Varrot, A., Imberty, A., Kuhn, B., Lerner, C., Grether, U., & Titz, A. (2025). The Parkinson's Disease Drug Tolcapone and Analogues are Potent Glycomimetic Lectin Inhibitors of Pseudomonas aeruginosa LecA. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202508864

Vancouver

Leusmann S, Siebs E, Kuhaudomlarp S, Varrot A, Imberty A, Kuhn B, et al. The Parkinson's Disease Drug Tolcapone and Analogues are Potent Glycomimetic Lectin Inhibitors of Pseudomonas aeruginosa LecA. Angewandte Chemie International Edition. 2025. doi:10.1002/anie.202508864

BibTeX
@article{Leusmann2025,
  author = {Leusmann, Steffen and Siebs, Eike and Kuhaudomlarp, Sakonwan and Varrot, Annabelle and Imberty, Anne and Kuhn, Bernd and Lerner, Christian and Grether, Uwe and Titz, Alexander},
  title = {The Parkinson's Disease Drug Tolcapone and Analogues are Potent Glycomimetic Lectin Inhibitors of Pseudomonas aeruginosa LecA},
  journal = {Angewandte Chemie International Edition},
  year = {2025},
  doi = {10.1002/anie.202508864}
}
Kostenlos starten →